Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.15 - $0.54 $4,500 - $16,200
-30,000 Reduced 47.28%
33,451 $5,000
Q1 2022

May 02, 2022

SELL
$0.36 - $0.57 $18,000 - $28,499
-50,000 Reduced 44.07%
63,451 $33,000
Q4 2021

Feb 15, 2022

BUY
$0.46 - $0.94 $41,400 - $84,600
90,000 Added 383.78%
113,451 $59,000
Q3 2021

Nov 10, 2021

SELL
$0.86 - $1.21 $94,600 - $133,100
-110,000 Reduced 82.43%
23,451 $21,000
Q2 2021

Aug 11, 2021

BUY
$1.04 - $1.69 $57,200 - $92,950
55,000 Added 70.11%
133,451 $159,000
Q1 2021

May 05, 2021

SELL
$1.32 - $3.79 $165,000 - $473,750
-125,000 Reduced 61.44%
78,451 $127,000
Q4 2020

Feb 16, 2021

BUY
$1.06 - $1.51 $111,300 - $158,550
105,000 Added 106.65%
203,451 $252,000
Q3 2020

Nov 17, 2020

BUY
$1.15 - $2.1 $11,500 - $21,000
10,000 Added 11.31%
98,451 $134,000
Q2 2020

Aug 13, 2020

SELL
$0.48 - $1.67 $16,800 - $58,450
-35,000 Reduced 28.35%
88,451 $112,000
Q1 2020

May 13, 2020

SELL
$0.28 - $1.23 $2,800 - $12,300
-10,000 Reduced 7.49%
123,451 $80,000
Q4 2019

Feb 10, 2020

BUY
$0.96 - $2.94 $57,600 - $176,400
60,000 Added 81.69%
133,451 $156,000
Q3 2019

Nov 14, 2019

BUY
$0.58 - $3.01 $11,600 - $60,199
20,000 Added 37.42%
73,451 $184,000
Q2 2019

Aug 13, 2019

SELL
$1.47 - $3.16 $31,677 - $68,094
-21,549 Reduced 28.73%
53,451 $90,000
Q1 2019

May 13, 2019

SELL
$2.56 - $4.48 $64,000 - $112,000
-25,000 Reduced 25.0%
75,000 $197,000
Q4 2018

Feb 05, 2019

BUY
$2.98 - $6.86 $71,520 - $164,640
24,000 Added 31.58%
100,000 $301,000
Q3 2018

Oct 29, 2018

SELL
$5.36 - $7.83 $76,203 - $111,319
-14,217 Reduced 15.76%
76,000 $566,000
Q2 2018

Aug 07, 2018

BUY
$5.97 - $9.58 $538,595 - $864,278
90,217 New
90,217 $698,000

About T2 Biosystems, Inc.


  • Ticker TTOO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 7,050,850
  • Market Cap $3.38M
  • Description
  • T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fl...
More about TTOO
Track This Portfolio

Track Levin Capital Strategies, L.P. Portfolio

Follow Levin Capital Strategies, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Levin Capital Strategies, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Levin Capital Strategies, L.P. with notifications on news.